Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
A smart investment strategy is to diversify your portfolio with both stable, established companies and growth stocks. Growth ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...